The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
23 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,004,018 in first-year total cost, median $221,850.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OBT-R (55)]13
- Special Emphasis Panel[ZRG1 OBT-D (55)]4
- Special Emphasis Panel[ZRG1 OBT-B (55)]3
- Special Emphasis Panel[ZRG1 OBT-K (55)]3
Most frequent institutions
- H. LEE MOFFITT CANCER CTR & RES INST2
- UNIVERSITY OF SOUTHERN CALIFORNIA2
- COMPREHENSIVE CANCER CENTER/ UNIV/PR1
- DUKE UNIVERSITY1
- EMORY UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy1R21CA260084-01 | ADEEGBE, DENNIS O | H. LEE MOFFITT CANCER CTR & RES INST, FL | $423,486 | ZRG1 |
| 2021 | Reversing molecular cancer phenotypes by targeting epigenetic alterations in prostate cancer1R21CA260082-01 | RHIE, SUHN KYONG | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $385,688 | ZRG1 |
| 2021 | Oncolytic Adenovirus Armed with SA-4-1BBL Immune Checkpoint Stimulator for Lung Cancer Immunotherapy1R21CA249348-01A1 | GOMEZ-GUTIERREZ, JORGE G | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $352,332 | ZRG1 |
| 2021 | Targeting sfRon-S6K1 signaling and mitotic kinesin Eg5 in ovarian cancer: a novel synergistic treatment strategy1R21CA264573-01 | BIENIASZ, MAGDALENA | OKLAHOMA MEDICAL RESEARCH FOUNDATION, OK | $245,157 | ZRG1 |
| 2021 | The Role of Base Excision Repair in Regulating DNA-Mediated Inflammatory Signaling Pathways1R21CA249346-01A1 | KIDANE MULAT, DAWIT | UNIVERSITY OF TEXAS AT AUSTIN, TX | $212,005 | ZRG1 |
| 2021 | Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolution1R21CA264637-01 | RHIE, SUHN KYONG | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $192,844 | ZRG1 |
| 2021 | Cross Sectional Association of the Oral Microbiota and the Inflammasome with Oral HPV among HIV+ Adults1R21CA264606-01 | PEREZ-SANTIAGO, JOSUE | COMPREHENSIVE CANCER CENTER/ UNIV/PR, PR | $173,511 | ZRG1 |
| 2021 | Evolutionary trajectories of tumors following resistance to immune checkpoint blockade1R21CA264599-01 | REEVES, MELISSA QUINO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $92,836 | ZRG1 |
| 2020 | Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy1R21CA253555-01 | ARMAIZ-PENA, GUILLEROMO N | PONCE SCHOOL OF MEDICINE, PR | $438,076 | ZRG1 |
| 2020 | Phospholipase D1 and pancreatic cancer1R21CA227416-01A1 | MACKENZIE, GERARDO GUILLERMO | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $403,688 | ZRG1 |
| 2020 | Understanding the effects of adjuvant endocrine therapy on thermoregulation1R21CA249338-01A1 | CORREA, STEPHANIE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $401,115 | ZRG1 |
| 2020 | Transcriptional effects and non-transcriptional effects of estrogen in the pathogenesis of Inflammatory Breast Cancer1R21CA253609-01 | PETERSON, ESTHER A | UNIVERSITY OF PUERTO RICO RIO PIEDRAS, PR | $379,825 | ZRG1 |
| 2020 | Examining differential effects of obesity on inflammation in ex-smokers to understand racial disparities in cancer risk1R21CA249357-01A1 | TAN, MARCIA MCNUTT | UNIVERSITY OF CHICAGO, IL | $297,374 | ZRG1 |
| 2020 | Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness1R21NS120800-01 | ETAME, ARNOLD | H. LEE MOFFITT CANCER CTR & RES INST, FL | $247,050 | ZRG1 |
| 2020 | Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential1R21CA253645-01 | MOTEA, EDWARD AYSON | INDIANA UNIVERSITY INDIANAPOLIS, IN | $222,296 | ZRG1 |
| 2020 | Targeting Liver-X-Receptor Regulation of Prostate Cancer Immune-Evasion1R21CA249341-01 | FLAVENY, COLIN ASHTON | SAINT LOUIS UNIVERSITY, MO | $212,479 | ZRG1 |
| 2020 | Combinatorial Strategies for the Treatment of Brain Metastases1R21CA249349-01 | SOTO PANTOJA, DAVID R. | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $181,156 | ZRG1 |
| 2019 | A new kinase inhibitor for glioblastoma1R21CA243036-01 | BLIND, RAYMOND DANIEL | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $221,850 | ZRG1 |
| 2019 | Glycosphingolipid Alterations in Lung Cancer1R21CA232234-01A1 | LIMA, SANTIAGO | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $202,601 | ZRG1 |
| 2019 | High-throughput identification of novel therapeutic targets in lung cancer from genes with altered mRNA splicing1R21CA238600-01 | BROOKS, ANGELA NORIE | UNIVERSITY OF CALIFORNIA SANTA CRUZ, CA | $196,899 | ZRG1 |
| 2019 | Predictable control of gene regulation through epigenetic engineering1R21CA232244-01A1 | HAYNES, KARMELLA ANN | EMORY UNIVERSITY, GA | $179,671 | ZRG1 |
| 2019 | Characterization of NYP Peptides in Prostate Cancer1R21CA238343-01 | MACIAS, EVERARDO | DUKE UNIVERSITY, NC | $174,817 | ZRG1 |
| 2019 | A Big Data Approach to BCR ABL Leukemias1R21CA232249-01A1 | MITCHELL, CASSIE S | GEORGIA INSTITUTE OF TECHNOLOGY, GA | $167,262 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.